GENSCRIPT BIO (01548) announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported revenue from continuing operations of $519 million, representing an 81.92% year-over-year increase. Loss attributable to owners of the parent company was $25.462 million, narrowing by 85.46% compared to the same period last year. Basic loss per share stood at 1.18 cents.

According to the announcement, revenue from life science services and products reached approximately $248 million during the reporting period, up 11.3% from approximately $222 million in the previous period. Adjusted gross profit was approximately $126 million, increasing 5.3% from approximately $120 million in the prior period. The adjusted gross profit margin decreased slightly to 51.0% from 53.9% in the previous period. Adjusted operating profit declined slightly to approximately $46.4 million from approximately $47.8 million in the previous period.

The increase in revenue and adjusted gross profit was primarily attributed to: (i) reliable, rapid, and high-quality service and product delivery achieved through platform innovation and automation upgrades, particularly in protein and gene editing platforms; (ii) further improved operational efficiency at production facilities in mainland China, Singapore, and the United States; and (iii) enhanced customer engagement through targeted activities and brand repositioning.

The decrease in adjusted operating profit was due to increased investments in marketing transformation and research and development activities to build medium to long-term competitiveness.